Tonmya is a drug owned by Tonix Pharmaceuticals Inc. It is protected by 4 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 14, 2034. Details of Tonmya's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10117936 | NA |
Mar, 2034
(8 years from now) | Active |
| US10864175 | NA |
Mar, 2034
(8 years from now) | Active |
| US9636408 | NA |
Mar, 2034
(8 years from now) | Active |
| US9956188 | NA |
Mar, 2034
(8 years from now) | Active |
FDA has granted several exclusivities to Tonmya. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Tonmya, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Tonmya.
Exclusivity Information
Tonmya holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Tonmya's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 15, 2028 |
US patents provide insights into the exclusivity only within the United States, but Tonmya is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tonmya's family patents as well as insights into ongoing legal events on those patents.
Tonmya's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tonmya's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 14, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tonmya Generic API suppliers:
Cyclobenzaprine Hydrochloride is the generic name for the brand Tonmya. 23 different companies have already filed for the generic of Tonmya, with Rising having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tonmya's generic
Alternative Brands for Tonmya
There are several other brand drugs using the same active ingredient (Cyclobenzaprine Hydrochloride) as Tonmya. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Teva Pharms Intl |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Cyclobenzaprine Hydrochloride, Tonmya's active ingredient. Check the complete list of approved generic manufacturers for Tonmya
About Tonmya
Tonmya is a drug owned by Tonix Pharmaceuticals Inc. Tonmya uses Cyclobenzaprine Hydrochloride as an active ingredient. Tonmya was launched by Tonix in 2025.
Approval Date:
Tonmya was approved by FDA for market use on 15 August, 2025.
Active Ingredient:
Tonmya uses Cyclobenzaprine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Cyclobenzaprine Hydrochloride ingredient
Dosage:
Tonmya is available in tablet form for sublingual use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2.8MG | TABLET | Prescription | SUBLINGUAL |